Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Text availability
Article attribute
Article type
Publication date

Search Results

198 results
Filters applied: . Clear all Results are displayed in a computed author sort order. Results by year timeline is unavailable
Page 1
New directions in the treatment of mantle cell lymphoma: an overview.
Goy A. Goy A. Clin Lymphoma Myeloma. 2006 Oct;7 Suppl 1:S24-32. doi: 10.3816/clm.2006.s.005. Clin Lymphoma Myeloma. 2006. PMID: 17101070 Review.
Allogenic transplantation represents a potential curative option for MCL, especially nonmyeloablative transplantation, more feasible in that population. ...A molecular approach to define biomarkers might help identify subgroups of patients and help develop rational …
Allogenic transplantation represents a potential curative option for MCL, especially nonmyeloablative transplantation, more feasible …
Frequency of gastrointestinal involvement and its clinical significance in mantle cell lymphoma.
Romaguera JE, Medeiros LJ, Hagemeister FB, Fayad LE, Rodriguez MA, Pro B, Younes A, McLaughlin P, Goy A, Sarris AH, Dang NH, Samaniego F, Brown HM, Gagneja HK, Cabanillas F. Romaguera JE, et al. Among authors: goy a. Cancer. 2003 Feb 1;97(3):586-91. doi: 10.1002/cncr.11096. Cancer. 2003. PMID: 12548600
METHODS: From March 1998 to May 2001 baseline upper and lower endoscopy of the GI tract was performed in consecutive untreated patients with MCL as part of a prospective therapeutic trial. ...CONCLUSIONS: Gastrointestinal tract involvement was found to be present in most p …
METHODS: From March 1998 to May 2001 baseline upper and lower endoscopy of the GI tract was performed in consecutive untreated patients with …
Update on the proteasome inhibitor bortezomib in hematologic malignancies.
Goy A, Gilles F. Goy A, et al. Clin Lymphoma. 2004 Mar;4(4):230-7. doi: 10.3816/clm.2004.n.003. Clin Lymphoma. 2004. PMID: 15072615 Review.
The ubiquitin-proteasome system plays a crucial role in eukaryotic cells in maintaining protein homeostasis. Through the disruption of a variety of pathways and cell cycle checkpoints, proteasome inhibition leads to apoptosis and in experimental models can overcome …
The ubiquitin-proteasome system plays a crucial role in eukaryotic cells in maintaining protein homeostasis. Through the disruption o …
Establishment and characterization of a new mantle cell lymphoma cell line M-1.
Goy A, Remache YK, Gu J, Stewart J, Hayes KJ, Gold D, Jiang Y, Barkoh BA, Katz R, Cabanillas F, Gilles F. Goy A, et al. Leuk Lymphoma. 2004 Jun;45(6):1255-60. doi: 10.1080/10428190310001642729. Leuk Lymphoma. 2004. PMID: 15360009
A new mantle cell lymphoma cell line, M-1, was established from peripheral blood mononuclear cells of a patient with a diagnosis of blastoid variant of mantle cell lymphoma in leukemic phase. ...The effect of the drugs was evaluated by a 24 h cytotoxic
A new mantle cell lymphoma cell line, M-1, was established from peripheral blood mononuclear cells of a patient with a
High rate of durable remissions after treatment of newly diagnosed aggressive mantle-cell lymphoma with rituximab plus hyper-CVAD alternating with rituximab plus high-dose methotrexate and cytarabine.
Romaguera JE, Fayad L, Rodriguez MA, Broglio KR, Hagemeister FB, Pro B, McLaughlin P, Younes A, Samaniego F, Goy A, Sarris AH, Dang NH, Wang M, Beasley V, Medeiros LJ, Katz RL, Gagneja H, Samuels BI, Smith TL, Cabanillas FF. Romaguera JE, et al. Among authors: goy a. J Clin Oncol. 2005 Oct 1;23(28):7013-23. doi: 10.1200/JCO.2005.01.1825. Epub 2005 Sep 6. J Clin Oncol. 2005. PMID: 16145068 Clinical Trial.
PATIENTS AND METHODS: This was a prospective phase II trial of rituximab plus fractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone (hyper-CVAD; considered one cycle) alternating every 21 days with rituximab plus high-dose methotrexate-cytarabine (cons …
PATIENTS AND METHODS: This was a prospective phase II trial of rituximab plus fractionated cyclophosphamide, vincristine, doxorubicin …
The feasibility of gene expression profiling generated in fine-needle aspiration specimens from patients with follicular lymphoma and diffuse large B-cell lymphoma.
Goy A, Stewart J, Barkoh BA, Remache YK, Katz R, Sneige N, Gilles F. Goy A, et al. Cancer. 2006 Feb 25;108(1):10-20. doi: 10.1002/cncr.21500. Cancer. 2006. PMID: 16329118
Lymphoma of germinal center cell (GC) origin generally is an indolent malignancy that transforms progressively into a more aggressive disease. ...Gene expression profiling results were analyzed first by principal-component analysis (PCA) by using a list of 146 probe …
Lymphoma of germinal center cell (GC) origin generally is an indolent malignancy that transforms progressively into a more aggressive …
Multicenter phase II study of bortezomib in patients with relapsed or refractory mantle cell lymphoma.
Fisher RI, Bernstein SH, Kahl BS, Djulbegovic B, Robertson MJ, de Vos S, Epner E, Krishnan A, Leonard JP, Lonial S, Stadtmauer EA, O'Connor OA, Shi H, Boral AL, Goy A. Fisher RI, et al. Among authors: goy a. J Clin Oncol. 2006 Oct 20;24(30):4867-74. doi: 10.1200/JCO.2006.07.9665. Epub 2006 Sep 25. J Clin Oncol. 2006. PMID: 17001068 Clinical Trial.
PATIENTS AND METHODS: Bortezomib 1.3 mg/m(2) was administered on days 1, 4, 8, and 11 of a 21-day cycle, for up to 17 cycles. ...Median OS has not been reached after a median follow-up of 13.4 months. The safety profile of bortezomib was similar to previous experien …
PATIENTS AND METHODS: Bortezomib 1.3 mg/m(2) was administered on days 1, 4, 8, and 11 of a 21-day cycle, for up to 17 cycles. ...Medi …
Mantle cell lymphoma: evolving novel options.
Goy A. Goy A. Curr Oncol Rep. 2007 Sep;9(5):391-8. doi: 10.1007/s11912-007-0053-9. Curr Oncol Rep. 2007. PMID: 17706168 Review.
Expanding therapeutic options in mantle cell lymphoma.
Goy A, Feldman T. Goy A, et al. Clin Lymphoma Myeloma. 2007 Aug;7 Suppl 5:S184-91. doi: 10.3816/clm.2007.s.021. Clin Lymphoma Myeloma. 2007. PMID: 17877843 Review.
Mantle cell lymphoma (MCL) still carries a poor prognosis. Chemoimmunotherapy (combination with rituximab) is the routine first-line therapy, although data strongly suggest a benefit from intensification through high-dose therapy with stem cell transplantation conso …
Mantle cell lymphoma (MCL) still carries a poor prognosis. Chemoimmunotherapy (combination with rituximab) is the routine first-line …
Bortezomib in mantle cell lymphoma.
Suh KS, Goy A. Suh KS, et al. Among authors: goy a. Future Oncol. 2008 Apr;4(2):149-68. doi: 10.2217/14796694.4.2.149. Future Oncol. 2008. PMID: 18407730 Review.
Most patients still relapse and a multitude of novel agents are currently being tested in this setting, including proteasome inhibitors with bortezomib (the first of its class and the first US FDA-approved drug for MCL), mTOR inhibitors, Bcl-2 inhibitors, antiangiogenesis …
Most patients still relapse and a multitude of novel agents are currently being tested in this setting, including proteasome inhibito …
198 results
Jump to page
Feedback